MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Audio By Carbonatix

NEW YORK--(BUSINESS WIRE)--Oct 24, 2024--

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the third quarter ended September 30, 2024.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241024456529/en/

CONTACT: For Media:[email protected]

For Investors:[email protected]

KEYWORD: NEW YORK EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY NEUROLOGY MENTAL HEALTH HEALTH PHARMACEUTICAL

SOURCE: Mind Medicine Inc.

Copyright Business Wire 2024.

PUB: 10/24/2024 07:00 AM/DISC: 10/24/2024 07:02 AM

http://www.businesswire.com/news/home/20241024456529/en